RxDoctor Payments Data

Tenaea Jeppeson

Psychiatric/Mental Health · Fort Dodge, IANPI 1043703887

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $35,750 of the $38,371 with a category attached, or 93.2%. AbbVie accounts for 99.9% of it on its own, with 3 other manufacturers making up the rest. Among psychiatric/mental health clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$38,371in general payments, 2019–2025

Across 78 payments — averaging $491.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$38K
  • Alkermes, Inc.$23
  • Sunovion Pharmaceuticals Inc.$12
  • Otsuka America Pharmaceutical, Inc.$11

What the payments were for

  • Speaking & faculty fees$35,75093%
  • Travel & lodging$1,7635%
  • Food & beverage$8582%

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$38,371 in reported general payments places this provider in the 95th percentile of 443 psychiatric/mental health providers in Iowa.

See all psychiatric/mental health providers in Iowa

Medicare billing

Part B allowed, 2024
$17,877
Medicare patients
69
Services billed
243

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl72$107,757
RexultiBrexpiprazole58$91,923
IngrezzaValbenazine Tosylate12$86,098
AristadaAripiprazole Lauroxil14$48,217
Abilify MaintenaAripiprazole12$25,439
PerserisRisperidone11$23,529
TrintellixVortioxetine Hydrobromide36$21,534
CaplytaLumateperone Tosylate12$20,404
Aripiprazole115$11,867
Lurasidone Hcl78$7,857
Clozapine60$6,523
Quetiapine Fumarate235$6,176
Lisdexamfetamine Dimesylate34$5,790
VyvanseLisdexamfetamine Dimesylate16$5,727
Divalproex Sodium ErDivalproex Sodium14$5,319

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$11$117,36170 claims
AbbVieVraylar$38,324$107,75772 claims
Alkermes, Inc.Aristada$23$48,21714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 443 psychiatric/mental health providers in Iowa.

Other psychiatric/mental health in Fort Dodge

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →